検体妥当性試験の世界市場（2022年～2029年）

当レポートでは、世界の検体妥当性試験市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界の検体妥当性試験市場の調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 世界の検体妥当性試験市場－市場の定義と概要

第3章 世界の検体妥当性試験市場－エグゼクティブサマリー

• 市場の内訳：製品・サービス別
• 市場の内訳：タイプ別
• 市場の内訳：エンドユーザー別
• 市場の内訳：地域別

第4章 世界の検体妥当性試験市場－市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の検体妥当性試験市場－業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 世界の検体妥当性試験市場－COVID-19分析

• 市場のCOVID-19分析
  • COVID-19以前の市場シナリオ
  • 現在のCOVID-19の市場シナリオ
  • COVID-19以後の市場シナリオ/将来の市場シナリオ
• COVID-19における価格の力学
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 世界の検体妥当性試験市場：製品・サービス別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：製品・サービス別
  • 市場魅力指数：製品・サービス別
• 製品
• サービス

第8章 世界の検体妥当性試験市場：タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：タイプ別
  • 市場魅力指数：タイプ別
• ラボ試験*
• 迅速/POCテスト

第9章 世界の検体妥当性試験市場：エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：エンドユーザー別
  • 市場魅力指数：エンドユーザー別
• 薬物スクリーニングラボ*
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
• 疼痛管理センター
• その他

第10章 世界の検体妥当性試験市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）：地域別
  • 市場魅力指数：地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東とアフリカ

第11章 世界の検体妥当性試験市場－競合情勢

• 主な開発と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 世界の検体妥当性試験市場－企業プロファイル概要

• Thermo Fisher Scientific*
  • 企業概要
  • 製品ポートフォリオおよび説明
  • 主要ハイライト
  • 財務概要
• Abbott Laboratories
• American Bio Medica Corporation
• Premier Biotech, Inc.
• Sciteck
• LabCorp

第13章 世界の検体妥当性試験市場－DataM

• 付録
• 当社・サービスについて
• 問い合わせ先

Market Overview

The global specimen validity testing market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The test method used to determine if a urine specimen is abnormal or tampered with is known as Specimen Validity Testing (SVT), also known as adulteration testing.

Market Dynamics

The factors expected to drive the growth of the global specimen validity testing market are the growing need for drug screening and the increasing number of drug abuse cases.

The growing demand for drug screening is expected to drive market growth in the forecast period

Heroin, cocaine, marijuana, hallucinogens, inhalants, and nonmedical use of prescription psychotherapeutics are all examples of illegal drug use (stimulants, tranquilizers, and painkillers). According to the National Center for Drug Abuse Statistics, over a year, 10.1 million Americans, or 3.7 percent, misuse opioids at least once. An opioid use disorder affects 1.6 million people or 15.8% of the population. Prescription pain relievers are used by 9.7 million opioid abusers or 96.6 percent. Urine drug screening is a clinical method that can improve hospital safety, track patient compliance with treatment, diagnose drug abuse (illicit and legal), and prescription drug diversion.

Urine drug screening is a clinical tool for improving workplace safety, monitoring patient medication compliance, and detecting drug (illicit and prescription) abuse and prescription medication diversion. Because drug testing has personal, occupational, and legal ramifications, pain specialists and primary care physicians must be confident in their ability to interpret urine drug assay results to respond appropriately to improve clinical outcomes. Many companies are offering specimen validity testing. For instance, to help determine if a valid urine sample is being tested, Siemens Healthineers offers five specimen validity tests. The Atellica CH Analyzer, ADVIA Chemistry Systems, and Viva Drug Testing Systems have tests. Hence, with the growing need for drug screening, the global specimen validity testing market is expected to grow in the forecast period.

The problems associated with specimen validity testing is expected to hamper the market growth

The overpayment for specimen validity testing is expected to affect the market growth. For instance, Medicare overpaid providers for medically unnecessary specimen validity tests performed with urine drug tests. Medicare billing requirements were not followed when providers made payments for specimen validity tests. For specimen validity tests billed with urine drug tests, Medicare improperly paid $66.3 million to 4,480 clinical laboratories and physician offices. According to officials with the Centers for Medicare & Medicaid Services, medically necessary tests used to diagnose certain conditions performed on the same day as a urine drug test for a single beneficiary should be a rare occurrence (CMS). Payments for specimen validity tests billed in conjunction with urine drug tests were improperly paid because providers did not follow existing Medicare guidance. CMS's system edits were insufficient to prevent payment. CMS and most Medicare contractors issued additional guidance on specimen validity testing. Hence, the payment issues related to specimen validity testing are expected to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has posed significant challenges to healthcare systems and public health policies worldwide. It necessitates the development of novel treatment and prevention strategies to adapt to the pandemic's impact. Multiple factors attributable to their clinical, psychological, and psychosocial conditions put people with substance use disorders (SUD) at risk for contamination. Furthermore, the social and economic changes brought on by the pandemic and the traditional challenges of treatment access and adherence will almost certainly worsen during this time, exacerbating their situation. It is well understood that the presence and severity of SUD are linked to - and can impact clinical and psychological conditions. Hence, with increasing drug abuse cases due to covid-19 impact, the demand for the specimen validity testing market is expected to grow in the forecast period.

Segment Analysis

The laboratory testing segment is expected to dominate the market growth

The key factors driving demand for this segment include the accuracy of test results and the cost-effectiveness of laboratory testing. For instance, sample tampering, substitution, and adulteration are all possibilities. When these practices occur, the specimen is deemed invalid, resulting in erroneous test results. Substitution, tampering, and adulteration techniques can be sophisticated and difficult to detect in situations where individuals attempt to evade detection of certain drug use or diversion. Drug testing continues to be hampered by using these avoidance techniques to mask controlled or illicit substances. To counter these efforts, the aforementioned entities mandate or require their certified laboratories to perform the following tests on all urine specimens submitted for drug testing creatinine, specific gravity, pH, one or more validity tests for oxidising adulterants, and additional validity tests when atypical results are found.

Screening tests (the initial tests) can detect the presence or absence of a substance or its metabolite, as well as a cross-reacting, chemically similar substance. Screening tests are usually performed in a lab or on-site (point-of-care test [POCT]) and use an immunoassay technique. Laboratory immunoassay screening tests are low-cost, simple to automate and provide quick results. Many companies offer laboratory testing, for instance, the most common way donors try to cheat a drug test is by using oxidising adulterants such as nitrites, chromates, and halogens. When a customer or Medical Review Officer requests oxidant identification for some of the most common oxidising adulterants, Quest diagnostics is one of the few laboratories that can provide it. When new adulterants become common, we monitor and adjust our testing as needed. To ensure accuracy, all "Invalid" specimens are tested twice on a different portion of the urine specimen based on analytical test results. Hence, the benefits offered by laboratories for specimen validity testing is expected to drive market growth.

Geographical Analysis

North America region is expected to hold the largest market share in the global specimen validity testing market

The factors influencing the specimen validity testing market are the increasing drug abuse population. For instance, in 2017, approximately 38% of adults struggled with an illicit drug use disorder. In the same year, one out of every eight adults struggled with alcohol and drug addiction. In 2017, 8.5 million adults in the United States had mental health and a substance use disorder, a condition known as co-occurring disorders. In the United States, active substance use disorders affect 22 million people. In the United States, the costs of tobacco, alcohol, illicit drugs, and prescription opioids to healthcare and society totaled more than 193 billion dollars for "illicit drugs," 78 billion dollars for prescription opioids, 250 billion dollars for alcohol use.

The government has established strict guidelines to address drug screening product adulteration, which is a major contributor to the specimen validity testing industry in North America. Another factor influencing the growth of the SVT (specimen validity testing) industry in North America is the emergence of a growing number of industries, as well as an increase in the number of pre-employment and random drug testing at work, which is fuelling the growth of the specimen validity testing market and ensuring the region's dominance. Hence, all these reasons are expected to drive the market growth in this region.

Competitive Landscape

With mergers, acquisitions, and product launches, the global specimen validity testing market is moderately competitive. Some of the key players in the market are Alere Inc., Thermo Fisher Scientific, LabCorp, American Bio Medica Corporation, Premier Biotech, Inc., Sciteck, Abbott Laboratories, Quest Laboratory Testing.

Thermo Fisher Scientific

Overview: Thermo Fisher Scientific is based in the United States that sells scientific

instruments, reagents and consumables, and software services. Waltham, Massachusetts, is the company's headquarters. The company was founded in 1956.

Product Portfolio: DRI General Oxidant-Detect Specimen Validity Test Calibrators with the liquid, ready-to-use this calibrator provides accuracy when testing for specimen adulterants on various general chemistry analyzers. Their product portfolio includes DRI General Oxidant-Detec Specimen Validity Test Controls, DRI Creatinine-Detect Specimen Validity Test Controls, DRI Indiko pH-Detect Specimen Validity Test.

Why Purchase the Report?

Visualize the composition of the global specimen validity testing market segmentation by product & services, by type, and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global specimen validity testing market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global specimen validity testing market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global specimen validity testing market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Global Specimen Validity Testing Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Specimen Validity Testing Market- Market Definition and Overview

3. Global Specimen Validity Testing Market- Executive Summary

• 3.1. Market Snippet By Product & Services
• 3.2. Market Snippet By Type
• 3.3. Market Snippet By End User
• 3.4. Market Snippet By Region

4. Global Specimen Validity Testing Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The growing demand for drug screening
  • 4.1.2. Restraints:
    • 4.1.2.1. The problems associated with specimen validity testing
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Specimen Validity Testing Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Global Specimen Validity Testing Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Specimen Validity Testing Market- By Product & Services

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 7.1.2. Market Attractiveness Index, By Product & Services
• 7.2. Products
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.2.1.2.1. Assay Kits
  • 7.2.1.2.2. Reagents and Calibrators
  • 7.2.1.2.3. Other
• 7.3. Services

8. Global Specimen Validity Testing Market-By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Laboratory Testing*
  • 8.2.1.1. Introduction
  • 8.2.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Rapid/POC Testing

9. Global Specimen Validity Testing Market- By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Drug Screening Laboratories*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Pain Management Centers
• 9.4. Other

10. Global Specimen Validity Testing Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.5.1. U.S.
    • 10.2.5.2. Canada
    • 10.2.5.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.5.1. Brazil
    • 10.4.5.2. Argentina
    • 10.4.5.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.5.1. China
    • 10.5.5.2. India
    • 10.5.5.3. Japan
    • 10.5.5.4. Australia
    • 10.5.5.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Specimen Validity Testing Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Global Specimen Validity Testing Market- Company Profiles

• 12.1. Thermo Fisher Scientific*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Abbott Laboratories
• 12.3. American Bio Medica Corporation
• 12.4. Premier Biotech, Inc.
• 12.5. Sciteck
• 12.6. LabCorp

LIST NOT EXHAUSTIVE

13. Global Specimen Validity Testing Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us